Depression - Pipeline Review, H2 2016

Date: September 21, 2016
Pages: 494
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: D58016CFAA6EN
Leaflet:

Download PDF Leaflet

Depression - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Depression - Pipeline Review, H2 2016’, provides an overview of the Depression pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Depression, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Depression and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape of Depression
  • The report reviews pipeline therapeutics for Depression by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Depression therapeutics and enlists all their major and minor projects
  • The report assesses Depression therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Depression
Reasons to buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Depression
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Depression pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope:
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Depression Overview
Therapeutics Development
Depression - Therapeutics under Development by Companies
Depression - Therapeutics under Investigation by Universities/Institutes
Depression - Pipeline Products Glance
Depression - Products under Development by Companies
Depression - Products under Investigation by Universities/Institutes
Depression - Companies Involved in Therapeutics Development
Depression - Therapeutics Assessment
Drug Profiles
Depression - Dormant Projects
Depression - Discontinued Products
Depression - Product Development Milestones
Appendix 474

LIST OF TABLES

Number of Products under Development for Depression, H2 2016
Number of Products under Development for Depression - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Development by Companies, H2 2016 (Contd..3)
Number of Products under Development by Companies, H2 2016 (Contd..4)
Number of Products under Development by Companies, H2 2016 (Contd..5)
Number of Products under Development by Companies, H2 2016 (Contd..6)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Development by Companies, H2 2016 (Contd..4)
Products under Development by Companies, H2 2016 (Contd..5)
Products under Development by Companies, H2 2016 (Contd..6)
Products under Development by Companies, H2 2016 (Contd..7)
Products under Development by Companies, H2 2016 (Contd..8)
Products under Development by Companies, H2 2016 (Contd..9)
Products under Development by Companies, H2 2016 (Contd..10)
Products under Investigation by Universities/Institutes, H2 2016
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
Depression - Pipeline by AB Science SA, H2 2016
Depression - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2016
Depression - Pipeline by Ache Laboratorios Farmaceuticos S/A, H2 2016
Depression - Pipeline by Adamed Sp. z o.o., H2 2016
Depression - Pipeline by Addex Therapeutics Ltd, H2 2016
Depression - Pipeline by Aequus Pharmaceuticals Inc., H2 2016
Depression - Pipeline by Alkermes Plc, H2 2016
Depression - Pipeline by Allergan Plc, H2 2016
Depression - Pipeline by Alvogen Korea Co., Ltd., H2 2016
Depression - Pipeline by Amorsa Therapeutics Inc., H2 2016
Depression - Pipeline by Anavex Life Sciences Corp., H2 2016
Depression - Pipeline by Angelini Group, H2 2016
Depression - Pipeline by Angita B.V., H2 2016
Depression - Pipeline by Araim Pharmaceuticals, Inc., H2 2016
Depression - Pipeline by AstraZeneca Plc, H2 2016
Depression - Pipeline by Avanir Pharmaceuticals, Inc., H2 2016
Depression - Pipeline by Axsome Therapeutics Inc, H2 2016
Depression - Pipeline by Azevan Pharmaceuticals, Inc., H2 2016
Depression - Pipeline by BioCrea GmbH, H2 2016
Depression - Pipeline by Biogen Inc, H2 2016
Depression - Pipeline by Biohaven Pharmaceutical Holding Company Limited, H2 2016
Depression - Pipeline by BioLite, Inc., H2 2016
Depression - Pipeline by Bionomics Limited, H2 2016
Depression - Pipeline by Boehringer Ingelheim GmbH, H2 2016
Depression - Pipeline by Bristol-Myers Squibb Company, H2 2016
Depression - Pipeline by Calico LLC, H2 2016
Depression - Pipeline by Celon Pharma Sp. z o.o., H2 2016
Depression - Pipeline by Cerecor Inc., H2 2016
Depression - Pipeline by Clera Inc., H2 2016
Depression - Pipeline by D-Pharm Ltd., H2 2016
Depression - Pipeline by Delpor, Inc., H2 2016
Depression - Pipeline by e-Therapeutics Plc, H2 2016
Depression - Pipeline by Eisai Co., Ltd., H2 2016
Depression - Pipeline by Eli Lilly and Company, H2 2016
Depression - Pipeline by Evotec AG, H2 2016
Depression - Pipeline by Fabre-Kramer Pharmaceuticals, Inc., H2 2016
Depression - Pipeline by GlaxoSmithKline Plc, H2 2016
Depression - Pipeline by GliaCure Inc., H2 2016
Depression - Pipeline by H. Lundbeck A/S, H2 2016
Depression - Pipeline by Heptares Therapeutics Limited, H2 2016
Depression - Pipeline by Hua Medicine (Shanghai) Ltd., H2 2016
Depression - Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016
Depression - Pipeline by Impel NeuroPharma, Inc., H2 2016
Depression - Pipeline by INSYS Therapeutics, Inc., H2 2016
Depression - Pipeline by Intas Pharmaceuticals Ltd., H2 2016
Depression - Pipeline by Intra-Cellular Therapies, Inc., H2 2016
Depression - Pipeline by INVENT Pharmaceuticals, Inc., H2 2016
Depression - Pipeline by Johnson & Johnson, H2 2016
Depression - Pipeline by KemPharm, Inc., H2 2016
Depression - Pipeline by Lead Discovery Center GmbH, H2 2016
Depression - Pipeline by Les Laboratoires Servier SAS, H2 2016
Depression - Pipeline by Lixte Biotechnology Holdings, Inc., H2 2016
Depression - Pipeline by Luye Pharma Group Ltd., H2 2016
Depression - Pipeline by Mapi Pharma Ltd., H2 2016
Depression - Pipeline by Mapreg S.A.S., H2 2016
Depression - Pipeline by Meta-IQ ApS, H2 2016
Depression - Pipeline by Methylation Sciences Inc., H2 2016
Depression - Pipeline by miCure Therapeutics Ltd., H2 2016
Depression - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016
Depression - Pipeline by Navya Biologicals Pvt Ltd, H2 2016
Depression - Pipeline by Neuralstem, Inc., H2 2016
Depression - Pipeline by Neurocrine Biosciences, Inc., H2 2016
Depression - Pipeline by NeuroNascent, Inc., H2 2016
Depression - Pipeline by NeurOp, Inc, H2 2016
Depression - Pipeline by Newron Pharmaceuticals S.p.A., H2 2016
Depression - Pipeline by Nippon Chemiphar Co., Ltd., H2 2016
Depression - Pipeline by nLife Therapeutics, S.L., H2 2016
Depression - Pipeline by Novartis AG, H2 2016
Depression - Pipeline by Omeros Corporation, H2 2016
Depression - Pipeline by Otsuka Holdings Co., Ltd., H2 2016
Depression - Pipeline by Pfizer Inc., H2 2016
Depression - Pipeline by Pherin Pharmaceuticals, Inc., H2 2016
Depression - Pipeline by Polleo Pharma Limited, H2 2016
Depression - Pipeline by Protagenic Therapeutics Inc., H2 2016
Depression - Pipeline by Relmada Therapeutics, Inc., H2 2016
Depression - Pipeline by Reviva Pharmaceuticals Inc., H2 2016
Depression - Pipeline by Richter Gedeon Nyrt., H2 2016
Depression - Pipeline by Saniona AB, H2 2016
Depression - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016
Depression - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016
Depression - Pipeline by Supernus Pharmaceuticals, Inc., H2 2016
Depression - Pipeline by Suven Life Sciences Ltd., H2 2016
Depression - Pipeline by Taisho Pharmaceutical Holdings Co., Ltd., H2 2016
Depression - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
Depression - Pipeline by Tetra Discovery Partners LLC, H2 2016
Depression - Pipeline by Trevena, Inc., H2 2016
Depression - Pipeline by TRImaran Pharma, Inc., H2 2016
Depression - Pipeline by Turing Pharmaceuticals AG , H2 2016
Depression - Pipeline by VistaGen Therapeutics , Inc., H2 2016
Depression - Pipeline by Zhejiang Huahai Pharmaceutical Co., Ltd., H2 2016
Depression - Pipeline by Zogenix, Inc., H2 2016
Depression - Pipeline by Zysis Limited, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Depression - Dormant Projects, H2 2016
Depression - Dormant Projects (Contd..1), H2 2016
Depression - Dormant Projects (Contd..2), H2 2016
Depression - Dormant Projects (Contd..3), H2 2016
Depression - Dormant Projects (Contd..4), H2 2016
Depression - Dormant Projects (Contd..5), H2 2016
Depression - Dormant Projects (Contd..6), H2 2016
Depression - Dormant Projects (Contd..7), H2 2016
Depression - Dormant Projects (Contd..8), H2 2016
Depression - Dormant Projects (Contd..9), H2 2016
Depression - Dormant Projects (Contd..10), H2 2016
Depression - Dormant Projects (Contd..11), H2 2016
Depression - Dormant Projects (Contd..12), H2 2016
Depression - Dormant Projects (Contd..13), H2 2016
Depression - Dormant Projects (Contd..14), H2 2016
Depression - Dormant Projects (Contd..15), H2 2016
Depression - Dormant Projects (Contd..16), H2 2016
Depression - Dormant Projects (Contd..17), H2 2016
Depression - Dormant Projects (Contd..18), H2 2016
Depression - Dormant Projects (Contd..19), H2 2016
Depression - Dormant Projects (Contd..20), H2 2016
Depression - Dormant Projects (Contd..21), H2 2016
Depression - Dormant Projects (Contd..22), H2 2016
Depression - Dormant Projects (Contd..23), H2 2016
Depression - Dormant Projects (Contd..24), H2 2016
Depression - Discontinued Products, H2 2016
Depression - Discontinued Products (Contd..1), H2 2016
Depression - Discontinued Products (Contd..2), H2 2016
Depression - Discontinued Products (Contd..3), H2 2016
Depression - Discontinued Products (Contd..4), H2 2016
Depression - Discontinued Products (Contd..5), H2 2016
Depression - Discontinued Products (Contd..6), H2 2016
Depression - Discontinued Products (Contd..7), H2 2016 483

LIST OF FIGURES

Number of Products under Development for Depression, H2 2016
Number of Products under Development for Depression - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Top 10 Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016
Skip to top


Depression - Pipeline Review, H1 2016 US$ 1,700.00 Mar, 2016 · 508 pages
Respiratory Depression - Pipeline Review, H1 2015 US$ 1,600.00 Mar, 2015 · 41 pages

Ask Your Question

Depression - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: